A new sclerosant therapy for testicular hydrocele with aspiration and injection of OK-432.
Twenty patients with testicular hydrocele were treated with a new sclerosing therapy consisting of intrascrotal injection of OK-432 (group A Streptococcus pyogenes of human origin). The median observation period after treatment was 6 months (range 2-13 months). Eighteen patients required only one treatment. Two patients had recurrences and received repeat injection. There have been no serious side effects except for fever of 2-3 days' duration and local inflammatory reaction. Sclerotherapy with OK-432 is an efficient and easy method which can be recommended as a primary treatment for hydrocele.
Yamamoto
M
M
Department of Urology, Nagoya University School of Medicine, Japan.
Hibi
H
H
Miyake
K
K
D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D008297:Male; D010844:Picibanil / Q000627:therapeutic use*; D015911:Sclerotherapy; D006848:Testicular Hydrocele / Q000628:therapy*
D010844:Picibanil